KRAS and non-small cell lung carcinoma: A small molecule screen found that HER, SHP2, mTOR and CDK4/CDK6 inhibitors increased the response rate to MRTX849 in KRASG12C mutant xenografts [28] STK11 co-mutations in KRAS mutant NSCLC have been associated with poor response to therapy [32,33,34]; the fact that mutation in this gene did not correlate with drug resistance in cell lines offers some hope for this generally refractory group.